A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 28 May 2013
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
- Sponsors Janssen Research & Development
- 21 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 22 Jul 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
- 22 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.